Moderna COVID/flu combo vaccine superior to separate shots in trial

10/6/2024 19:14

        Moderna said on Monday its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50
        and over when compared to separate shots against the viruses in a late-stage trial.
        
        In the study, the combination using messenger RNA technology generated greater antibodies than currently marketed traditional flu vaccines and Moderna's Spikevax mRNA COVID shot, the company said.
        
        The vaccine, called mRNA-1083, elicited a higher immune response against two A strains and one B strain of the flu in older adults when compared with widely used flu shots from GSK and Sanofi, according to the company.
        
        The U.S. Food and Drug Administration in March recommended drugmakers target those three strains, called H1N1, H3N2, and B/Victoria, when developing their seasonal flu vaccines for 2024.